Medtronic (MDT)

Some investors fear that President Donald Trump's aggressive tariffs will lead to economic troubles such as inflation. While things may or may not turn out that way, it's still a good idea to consider...

In the closing of the recent trading day, Medtronic (MDT) stood at $94.3, denoting a -1.5% move from the preceding trading day.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Medtronic (MDT) is undervalued, with strong organic growth and an 11% upside to a $105 target price, supporting a Buy rating. MDT's innovation pipeline, portfolio transformation, and spin-off of the d...

Technological advances are a key driver in the healthcare sector. One of the areas in which massive change has been taking place is surgery, with surgical robots helping to improve patient outcomes in...

Medtronic plc (NYSE:MDT ) Bank of America Global Healthcare Conference 2025 September 24, 2025 9:10 AM EDT Company Participants Thierry Pieton - Executive VP & CFO Presentation Unknown Analyst We're g...

MDT gains FDA approval for its Altaviva device, a minimally invasive bladder control therapy with long-lasting benefits.

Medtronic (MDT -0.68%) is out of favor today, noting it has a historically high dividend yield of around 3%. The company is working on improving its business performance, however, and stronger results...

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?

Medtronic remains a Buy for long-term investors, offering steady growth, durable income, and an attractive valuation below historical averages. MDT delivered solid fiscal Q1 2026 results, with 8.4% re...